Product Information
NAPROXEN DR 375 MG TABLET is a generic product labeled by ANI Pharmaceuticals, Inc., priced at $2.2343 per EA under NDC 70954092510. Its NADAC has been published 110 times since Aug 28, 2024.
FDA first approved this application on Jun 12, 2024. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Naproxen market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
375 mg/1
Manufacturer
ANI Pharmaceuticals, Inc.NDC
70954092510
Classification
Generic
Dosage Form
TABLET, DELAYED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
NAPROXENApproval Type
Generic (ANDA)
FDA Application
ANDA218497FDA Approved
6/12/2024
TE Code
AB
On Market Since
6/13/2024
Pharmacological Classes
Price Statistics
The NADAC for NAPROXEN DR 375 MG TABLET has been published 110 times since Aug 28, 2024, and over the history we have for it it has risen 1083.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.2343 per EA |
|---|---|
| All-time high | $2.4440 (May 13, 2026) |
| All-time low | $0.1888 (Aug 28, 2024) |
| 52-week high | $2.4440 |
| 52-week low | $1.2545 |
| Median price | $1.2523 |
| Average price | $1.3712 |
| Largest weekly change | +389.1% (Dec 18, 2024) |
| Weeks tracked | 110 |
| Tracking since | Aug 28, 2024 |
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 97% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ANI Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Naproxen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NAPROXEN DR 375 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for NAPROXEN DR 375 MG TABLET, manufactured by ANI Pharmaceuticals, Inc., is $2.2343 per EA (NDC 70954092510), effective Sep 30, 2026.
How has the price of NAPROXEN DR 375 MG TABLET changed over time?
Over the history we have for it, the NADAC for NAPROXEN DR 375 MG TABLET has risen 1083.3%. It has been tracked across 110 weekly CMS publications since Aug 28, 2024.
What are the highest and lowest recorded NADAC prices for NAPROXEN DR 375 MG TABLET?
Since Aug 28, 2024, the NADAC for NAPROXEN DR 375 MG TABLET has ranged from a low of $0.1888 (Aug 28, 2024) to a high of $2.4440 (May 13, 2026), with a median of $1.2523 per EA.
Are there cheaper alternatives to NAPROXEN DR 375 MG TABLET?
Yes. 9 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, NAPROXEN 375 MG TABLET, is $0.0573 per EA — about 97% below NAPROXEN DR 375 MG TABLET.
Who manufactures NAPROXEN DR 375 MG TABLET?
NAPROXEN DR 375 MG TABLET (NDC 70954092510) is labeled by ANI Pharmaceuticals, Inc., and CMS classifies it as a generic product.